Building Breakthroughs with Justin Gover
We recently welcomed Justin Gover, Founding CEO of GW Pharmaceuticals, to Under the Microscope for an engaging discussion hosted by Dick Pfister, CEO of AlphaCore Wealth Advisory, and Trevor Callan, Managing Partner.
Drawing on his experience leading GW Pharmaceuticals from startup to its $7.2 billion acquisition by Jazz Pharmaceuticals, Justin shared insights into the challenges and opportunities of building a pioneering biotech company. Through thoughtful questions from Dick and Trevor, the conversation explored innovation, leadership, strategic growth, capital raising, and the realities of scaling an organization in a highly regulated industry.
Justin also reflected on the development of Epidiolex, the first FDA-approved plant-derived cannabinoid medicine, and the lessons he learned translating scientific breakthroughs into meaningful patient impact. His perspectives on entrepreneurship, decision-making, and long-term value creation offered valuable takeaways for founders, investors, and business leaders alike.
At AlphaCore, we are committed to bringing our clients and community unique perspectives from accomplished leaders across business, investing, and innovation. We hope you enjoy this conversation between Justin, Dick, and Trevor and gain valuable insights from Justin’s remarkable entrepreneurial journey.
Disclosure: This material is being provided for informational purposes only. This material represents the current views and opinions of AlphaCore Capital, and there is no guarantee that any opinions will prove to be accurate, or any forecasts made will come to pass. No obligation is undertaken to update any information, data or material contained herein. AlphaCore provides investment advice only within the context of our written advisory agreement with each AlphaCore client. It may contain forward-looking statements regarding economic trends, market developments, or other factors. Actual results could differ materially from those expressed or implied. AlphaCore is not recommending the purchase, sale or holding of any security. Information provided does not constitute an offer or solicitation, and should not be considered tax, legal, or accounting advice.